Dafna Shelly

Cell-expansion technology is a critical component in various fields of biotechnology and regenerative medicine, focusing on the growth and proliferation of cells to meet the demands for clinical, research, and industrial applications. Cell-expansion technology is a cornerstone of modern biotechnology, enabling advances in medical treatments, drug development, and sustainable industrial processes. Ongoing innovations and improvements in this field hold great promise for addressing some of the most pressing challenges in health care, environmental sustainability, and cellular agriculture. In this interview with TechBullion, Lior Raviv, CTO at Pluri, shares how the company is pushing boundaries within the biotechnology industry. Read to find out more... #AGRITECH #BIOTECHNOLOGY #CELL #CELL-BASEDCOFFEE #CELLEXPANSION #CTO #FEATURED #FOODS #INTERVIEW #LIORRAVIV #PLURI #TECHNOLOGY

2

2 תגובות

It was great chatting with Rami Shani from Galei Tzahal, a leading Israeli radio station. Our VP R&D, Lior Kogut, discussed technology, healthcare, and the future of heart failure treatment (tune in at 37:27) Please note the podcast is in Hebrew. ‍  🎧 Listen here: https://lnkd.in/dT4afpuf   #medtech #heartfailure #glz

34

Research at the Technion's Faculty of Biology Paves the Way for Innovative Lung Cancer Treatment Researchers at the Technion's Faculty of Biology at Technion - Israel Institute of Technology have unveiled a promising new approach to treat lung cancer, particularly lung adenocarcinoma (LUAD). Led by Prof. Nabieh Ayoub and doctoral student feras machour, with contributions from Dr. Enas Rinawi and Alma Sophia Barisaac, the study was published in Nature Communications and named the Faculty of Biology’s "Article of the Month." Funded by the Israel Cancer Research Fund (ICRF) Research-Fund (ICRF), the research focused on the role of the RBM10 protein in LUAD and identified potential therapeutic targets for RBM10-deficient cancers. Preclinical trials have shown that inhibiting the WEE1 gene could be an effective treatment strategy, paving the way for new, personalized cancer therapies. read more here: https://lnkd.in/gfPRbtk2 #lungcancerresearch #cancertreatment #innovativemedicinee #cancertherapy #PersonalizedMedicine #adenocarcinoma #CancerGenomics

251

13 תגובות

May is National Cancer Research Month and throughout the month, we’ll be sharing how the Technion is revolutionizing approaches to cancer diagnosis and treatment. Learn more about how Technion - Israel Institute of Technology science is helping to overcome one of medicine's toughest challenges, cancer drug resistance. https://lnkd.in/gmBgbbE8  #TechnionImpact #NationalCancerResearchMonth

2

Immune Oncology Research Institute - Updates on the Breast Cancer Working Group https://lnkd.in/dG6CUx2B Yeolyan Hematology and Oncology Center, Ministry of Health of Armenia McGill University #Cancer #CancerResearch #BreastCancer #BreastCancerAwareness #ImmuneOncology #Histotype #Medicine #Health #Oncology #OncoDaily

21

About 3,000 Israelis die annually from COPD, a severe lung disease. Early diagnosis and proper treatment significantly improve the quality of life and life expectancy of patients. We see importance in raising awareness, understanding the disease and treatment methods in order to help patients and their families access treatment efficiently and quickly. The disease is Chronic Obstructive Pulmonary Disease, one of the most common, deadly, and lesser-known diseases, characterized by cumulative damage to lung function. According to the World Health Organization, the disease is the third leading cause of death worldwide. Despite this, between 70% and 80% of all patients in Israel are undiagnosed, and therefore do not receive appropriate treatment. About 400,000 Israelis suffer from the disease, and about 3,000 die from it every year. In 80% or more of cases, the main cause is cigarette smoking, but it can also be caused by exposure in workplaces, prolonged exposure to severe air pollution, untreated asthma, or even passive smoking. "There are many steps that can be taken to improve the quality of life of patients, slow down deterioration, and even prolong life," says Dr. Amir Bar-Shai >> https://lnkd.in/e_7JcsmB

1

Дарина, [12.06.2024 21:53] The Ediens team is currently working on the “Rapid Recovery project” We are conducting research with the military - we will take their gut microbiome, which we will study and correct with the help of our pharmabiotics Our goal is to create psychobiotics - medicines that regulate the mental health- for this we need to create a certain composition of bacteria For us, this is more than just a scientific work - it is something that can radically change the lives of our military and each of us! #Ediens #RapidRecovery #GutMicrobiome #Pharmabiotics #Psychobiotics #MentalHealth #ScientificResearch #Innovation #Healthcare #MilitaryHealthcare

1

Take a look at the latest video report by Види Вака - Vidi Vaka about what we do titled „Surgical revolution with 3D printed organ models". [the video is in Macedonian] #3DLoom #MedicalTechnology #AIinHealthcare #3DModeling #SurgicalInnovation #HealthcareTransformation

20

𝐇𝐨𝐰 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐀𝐫𝐞 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐔.𝐒 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲? 𝐓𝐡𝐞 𝐔.𝐒. 𝐫𝐚𝐫𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟏𝟐,𝟖𝟕𝟓.𝟖𝟒 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 𝐚𝐧𝐝 𝐢𝐬 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐝 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐟𝐫𝐨𝐦 𝐔𝐒𝐃 𝟏𝟒,𝟎𝟒𝟕.𝟒𝟔 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐭𝐨 𝐔𝐒𝐃 𝟐𝟖,𝟓𝟔𝟕.𝟖𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐢𝐧𝐠 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟗.𝟑% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝. 𝗚𝗲𝘁 𝗠𝗼𝗿𝗲 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: https://lnkd.in/dvmZ8JPf   𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬: • Rising awareness among healthcare providers about rare diseases • Development of advanced therapeutic methods • Increasing collaborations among market participants • Advent of novel technologies #rarediseasediagnostics #healthcareinnovation #rarediseases #medicaldiagnostics #ushealthcare #genetictesting #precisionmedicine #diagnosticmarket #rarediseaseawareness #medicalresearch

3

Mark your calendars! Our CEO, Or Retzkin will be presenting at Biomed Israel 2024 next Tuesday, May 21st, at 11:45 AM. Don't miss the opportunity to learn more about how EyeControl's latest innovations are making strides in preventing and managing in-hospital cognitive deterioration. See you there! #EyeControl #BiomedIsrael #BrainTech #PatientSafety #PatientOutcomes #Delirium #MedInnovation

16

#PRannouncement #StudyResults 𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐩𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐫𝐨𝐦 𝐨𝐮𝐫 𝐢𝐧-𝐯𝐢𝐯𝐨 𝐬𝐭𝐮𝐝𝐲 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧 𝐩𝐬𝐨𝐫𝐢𝐚𝐭𝐢𝐜 𝐬𝐤𝐢𝐧 𝐦𝐨𝐝𝐞𝐥 𝐭𝐫𝐚𝐧𝐬𝐩𝐥𝐚𝐧𝐭𝐞𝐝 𝐨𝐧𝐭𝐨 𝐦𝐢𝐜𝐞, 𝐥𝐞𝐝 𝐛𝐲 𝐏𝐫𝐨𝐟. amos gilhar 𝐨𝐟 𝐭𝐡𝐞 Technion - Israel Institute of Technology. 𝐓𝐡𝐞𝐬𝐞 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐜𝐨𝐧𝐟𝐢𝐫𝐦 𝐭𝐡𝐞 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬 𝐨𝐟 Scinai Immunotherapeutics Ltd. #𝐍𝐚𝐧𝐨𝐀𝐛 (𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐟𝐫𝐚𝐠𝐦𝐞𝐧𝐭, 𝐚𝐥𝐬𝐨 𝐜𝐚𝐥𝐥𝐞𝐝 𝐍𝐚𝐧𝐨𝐛𝐨𝐝𝐲®) 𝐢𝐧 𝐫𝐞𝐝𝐮𝐜𝐢𝐧𝐠 𝐤𝐞𝐲 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐨𝐫𝐲 𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐢𝐧 #𝐩𝐥𝐚𝐪𝐮𝐞_𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬. "𝑇ℎ𝑒𝑠𝑒 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑚𝑎𝑟𝑘 𝑎 𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑡 𝑠𝑡𝑒𝑝 𝑓𝑜𝑟𝑤𝑎𝑟𝑑 𝑖𝑛 𝑎𝑑𝑑𝑟𝑒𝑠𝑠𝑖𝑛𝑔 𝑡ℎ𝑒 𝑛𝑒𝑒𝑑𝑠 𝑜𝑓 𝑜𝑣𝑒𝑟 50% 𝑜𝑓 𝑝𝑠𝑜𝑟𝑖𝑎𝑠𝑖𝑠 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑠𝑢𝑓𝑓𝑒𝑟𝑖𝑛𝑔 𝑢𝑛𝑛𝑒𝑐𝑒𝑠𝑠𝑎𝑟𝑖𝑙𝑦," our CSO Dr. Tamar Ben-Yedidia explains. ,, "𝑆𝑐𝑖𝑛𝑎𝑖’𝑠 𝑛𝑜𝑣𝑒𝑙 𝑎𝑛𝑡𝑖-𝐼𝐿-17𝐴/𝐹 𝑛𝑎𝑛𝑜𝐴𝑏 𝑠ℎ𝑜𝑤𝑒𝑑 𝑔𝑟𝑒𝑎𝑡 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 𝑎𝑠 𝑎 𝑙𝑜𝑐𝑎𝑙 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑓𝑜𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑤𝑖𝑡ℎ 𝑚𝑖𝑙𝑑 𝑡𝑜 𝑚𝑜𝑑𝑒𝑟𝑎𝑡𝑒 𝑝𝑙𝑎𝑞𝑢𝑒 𝑝𝑠𝑜𝑟𝑖𝑎𝑠𝑖𝑠, 𝑒𝑠𝑝𝑒𝑐𝑖𝑎𝑙𝑙𝑦 𝑡ℎ𝑜𝑠𝑒 𝑤ℎ𝑜 𝑙𝑎𝑐𝑘 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑜𝑝𝑡𝑖𝑜𝑛𝑠". Current treatments can be burdensome and have side effects, leading to low adherence rates. The study results revealed that Scinai’s NanoAb had a similar therapeutic effect to the two leading comparator drugs. This is an important achievement because Scinai's product is not only intended to provide patients with a highly specific and convenient alternative with reduced risks for side effects but also comes with a low-frequency treatment schedule in comparison to the comparator drugs. We thank Prof. Amos Gilhar and his team at the Technion for their invaluable support. Looking ahead, we plan to refine dosing and conduct further studies, moving toward a first-in-human trial in late 2025 Follow the link to read the press release on our website: https://lnkd.in/dq7zPqtY #studyresults #DrugDevelopment #PsoriasisTreatment #innovation #newmilestone #biotech #pharma Amir Reichman Tamar Ben-Yedidia Dalit Fischer Elad Mark Liat Halpert Oded Ovadia

42

5 תגובות

✴ BGN's Bio Team shines at the Biomed Israel 2024 We had a strong presence at the recent Biomed Israel 2024 conference in Tel Aviv. Our bio team Galit Mazooz - Perlmuter 🎗 Ph.D Hagit Alon, (PhD) Micha Oestereich showcased cutting-edge technologies from Ben-Gurion University researchers and engaged in a whirlwind of activities. Our team had personal discussions with leading biotech and pharmaceutical companies, entrepreneurs who are seeking to adopt new technologies, venture capitalists, and industry colleagues. Conversations focused on potential collaborations, partnerships, and pathways to commercialize BGN's innovative biomedical technologies. The team also connected with existing partners like Magneto Thrombectomy Solutions, and OncoRedox Ltd., companies licensed by BGN .🤝 The goal was to drive innovation by facilitating the integration of Ben-Gurion's groundbreaking research into products and therapies. Through these meetings and networking opportunities, we took strides toward assimilating the university's biomedical breakthroughs into the broader life sciences industry. All in all, the Biomed Israel 2024 was a great opportunity to explore promising opportunities for Ben-Gurion's biomedical technologies. Josh Peleg #Biomed2024 #Biopharma #bioinnovation #Biotech

12

Come to hear about Precision medicine at Protai from Eran Seger, our CEO and co-founder, and learn about how the OrganoSphere initiative is going tp impact the Israeli industry. Irit Carmi-Levy | Eran Seger #PrecisionMedicine #Protai #OrganoSphere #HealthcareInnovation

43

We are thrilled to share an exclusive interview with Dr. Michal sheleg, Medical Director of Pluri, featured on DocWire News. Pluri is revolutionizing immunotherapy with their novel approach to solid tumor treatment using placenta-derived MAIT cells. 🧬 In this interview, Dr. Sheleg discusses: 🔹 Pluri's mission to transform cells into powerful products for diverse industries. 🔹 The unique benefits of MAIT cells, including their fast-acting nature and low risk of GVHD. 🔹 The groundbreaking 3D expansion technology developed by Pluri to enhance the quality and quantity of these cells. MAIT cells offer significant potential in overcoming challenges faced by conventional T cell therapies in solid tumor treatments. Pluri's innovative techniques could pave the way for new, effective cancer treatments. 🎯 To watch the full interview and learn more about how Pluri is setting new standards in the fight against cancer, see here: 👇 https://lnkd.in/g3evgK5E #Immunotherapy #CancerResearch #Biotechnology #HealthcareInnovation #Pluri #MAITCells

5

1 תגובה

We are happy to announce our exclusive training partnership with TWI Institute to enhance manufacturing workforce training and development. 🚀 🎉 “𝘉𝘺 𝘢𝘭𝘪𝘨𝘯𝘪𝘯𝘨 𝘰𝘶𝘳 𝘥𝘪𝘨𝘪𝘵𝘢𝘭 𝘱𝘭𝘢𝘵𝘧𝘰𝘳𝘮 𝘸𝘪𝘵𝘩 𝘱𝘳𝘰𝘷𝘦𝘯 𝘛𝘞𝘐 𝘐𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘵𝘳𝘢𝘪𝘯𝘪𝘯𝘨 𝘮𝘦𝘵𝘩𝘰𝘥𝘴, 𝘸𝘦 𝘢𝘳𝘦 𝘩𝘦𝘭𝘱𝘪𝘯𝘨 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴 𝘢𝘥𝘥𝘳𝘦𝘴𝘴 𝘴𝘰𝘮𝘦 𝘰𝘧 𝘵𝘩𝘦𝘪𝘳 𝘣𝘪𝘨𝘨𝘦𝘴𝘵 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴 — 𝘳𝘦𝘥𝘶𝘤𝘪𝘯𝘨 𝘵𝘳𝘢𝘪𝘯𝘪𝘯𝘨 𝘵𝘪𝘮𝘦, 𝘪𝘯𝘤𝘳𝘦𝘢𝘴𝘪𝘯𝘨 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘪𝘷𝘪𝘵𝘺, 𝘢𝘯𝘥 𝘪𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘴𝘢𝘧𝘦𝘵𝘺 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴. 𝘛𝘰𝘨𝘦𝘵𝘩𝘦𝘳, 𝘸𝘦 𝘢𝘳𝘦 𝘤𝘳𝘦𝘢𝘵𝘪𝘯𝘨 𝘢 𝘴𝘵𝘢𝘯𝘥𝘢𝘳𝘥𝘪𝘻𝘦𝘥, 𝘴𝘤𝘢𝘭𝘢𝘣𝘭𝘦 𝘴𝘰𝘭𝘶𝘵𝘪𝘰𝘯 𝘧𝘰𝘳 𝘤𝘰𝘮𝘱𝘢𝘯𝘪𝘦𝘴 𝘵𝘰 𝘥𝘦𝘷𝘦𝘭𝘰𝘱 𝘢𝘯𝘥 𝘳𝘦𝘵𝘢𝘪𝘯 𝘢 𝘴𝘬𝘪𝘭𝘭𝘦𝘥 𝘸𝘰𝘳𝘬𝘧𝘰𝘳𝘤𝘦.”  – Jerry Dolinsky CEO, Dozuki Together, TWI Institute's training methodology and Dozuki connected worker technology, companies can create a standardized, scalable solution to develop and retain a skilled workforce. Read our press release and view our recent webinar for more information (🔗link in the comments)!

15

2 תגובות

𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐧𝐮𝐭𝐫𝐢𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐜𝐚𝐧𝐜𝐞𝐫 𝐜𝐚𝐫𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟕.𝟏𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, 𝐞𝐱𝐡𝐢𝐛𝐢𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟒.𝟗% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝. 𝙈𝙤𝙧𝙚 𝙍𝙚𝙥𝙤𝙧𝙩 𝘿𝙚𝙩𝙖𝙞𝙡𝙨: https://lnkd.in/dwcD-fdb   The ability of nutritional support products to improve the immunity of cancer patients by providing the required amount of nutrients is primarily responsible for the market growth. Moreover, the implementation of strategic initiatives such as new product launches, merges, acquisitions, alliance, and partnerships contribute to the market #growth. #clinicalnutrition #cancercare #nutritionandcancer #oncologynutrition #cancernutrition #clinicaldiet #nutritiontherapy #medicalnutrition #cancerpatients #healthyeating #nutritionsupport 

2

We had a wonderful visit to the Gazit Lab, led by Prof. Ehud Gazit, Endowed Chair and the Academic Director of the BLAVATNIK CENTER for Drug Discovery - BCDD at Tel Aviv University. Prof. Gazit is one of the most active researchers at Ramot, responsible for numerous patents and spinoffs. His lab focuses on exploring biological and bio-inspired molecular self-assembly and adopts a minimalistic approach to defining small molecular recognition and assembly modules, studying their association in various biological systems. It identifies short peptides and metabolites forming amyloidal nano-fibrils and discovers a diverse family of dipeptide nanostructures with unique properties. Recent expansions include investigating peptide nucleic acids (PNA), merging peptide and DNA nanotechnology. It was a truly inspiring visit, and we can't wait to see the next groundbreaking technologies the lab team is working on. Prof. Ehud Gazit, Keren Primor Cohen, Tal Israeli Gassar, Liron Zusman-Azulay, Yair Eran #molecularselfassembly #innovation #research #biologicalassemblymodels #biotech #bioinnovation #researchinnovation

115

1 תגובה

𝗧𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗧𝟰 𝗗𝗡𝗔 𝗹𝗶𝗴𝗮𝘀𝗲 𝗺𝗮𝗿𝗸𝗲𝘁 𝘀𝗶𝘇𝗲 𝗶𝘀 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝘁𝗼 𝗿𝗲𝗮𝗰𝗵 𝗨𝗦𝗗 𝟮𝟮𝟯.𝟱𝟳 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟮, 𝗲𝘅𝗵𝗶𝗯𝗶𝘁𝗶𝗻𝗴 𝗮 𝗖𝗔𝗚𝗥 𝗼𝗳 𝟲.𝟮% 𝗱𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗽𝗲𝗿𝗶𝗼𝗱. 𝙈𝙤𝙧𝙚 𝙍𝙚𝙥𝙤𝙧𝙩 𝘿𝙚𝙩𝙖𝙞𝙡𝙨: https://lnkd.in/df6gDasz The #T4_DNA_ligase_market is experiencing significant growth driven by advancements in molecular biology and biotechnology research. This enzyme, crucial for DNA manipulation and cloning, plays a pivotal role in genetic engineering, synthetic biology, and genomics. As these fields continue to evolve, the demand for T4 DNA ligase has surged, supported by the increasing number of gene therapy-focused research projects and the rising interest in personalized medicine. The enzyme's ability to join DNA fragments efficiently makes it essential for various applications, including gene editing, DNA sequencing, and synthetic biology. #t4dnaligase #dnaligase #molecularbiology #geneticengineering #biotechnology #dnaresearch #genomics #dnarepair #geneticresearch #lifesciences #dnatechnology #genetherapy

6